Checkpoint Therapeutics (CKPT) Stock Forecast, Price Target & Predictions
CKPT Stock Forecast
Checkpoint Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CKPT Analyst Ratings
According to 3 Wall Street analysts, Checkpoint Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CKPT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 19, 2022 | B. Riley Securities | Buy | Buy | Hold |
| Jun 09, 2021 | B. Riley | - | Buy | Initialise |
| Jan 22, 2021 | Cantor Fitzgerald | - | Overweight | Initialise |
Checkpoint Therapeutics's last stock rating was published by B. Riley Securities on Dec 19, 2022. The company gave CKPT a "Buy" rating, the same as its previous rate.
Checkpoint Therapeutics Financial Forecast
Checkpoint Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $6.00K | $31.00K | - | $35.00K | $74.00K | $48.00K | $18.00K | $52.00K | - | $29.00K | $155.00K | $68.00K | $27.00K | $28.00K | $42.00K | $972.00K | $25.00K | $280.00K | $1.05M | $352.00K | $343.00K | $693.00K |
| Avg Forecast | $31.46M | $22.03M | $15.03M | $4.53M | $20.33K | $20.33K | $15.50K | $20.33K | $30.00K | $16.67K | $5.00K | $12.50K | $40.00K | $23.33K | $17.50K | $23.33K | $70.00K | $114.00K | $114.00K | $142.50K | $82.50K | $193.33K | $393.33K | $576.67K | $400.00K | $566.67K | $740.00K | $1.18M | $318.35K | $862.50K |
| High Forecast | $31.46M | $22.03M | $15.03M | $4.53M | $20.33K | $20.33K | $15.50K | $20.33K | $30.00K | $16.67K | $5.00K | $12.50K | $40.00K | $23.33K | $17.50K | $23.33K | $70.00K | $114.00K | $114.00K | $142.50K | $82.50K | $193.33K | $393.33K | $576.67K | $400.00K | $566.67K | $740.00K | $1.18M | $382.01K | $1.03M |
| Low Forecast | $31.46M | $22.03M | $15.03M | $4.53M | $20.33K | $20.33K | $15.50K | $20.33K | $30.00K | $16.67K | $5.00K | $12.50K | $40.00K | $23.33K | $17.50K | $23.33K | $70.00K | $114.00K | $114.00K | $142.50K | $82.50K | $193.33K | $393.33K | $576.67K | $400.00K | $566.67K | $740.00K | $1.18M | $254.68K | $690.00K |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 0.20% | 1.86% | - | 2.80% | 1.85% | 2.06% | 1.03% | 2.23% | - | 0.25% | 1.36% | 0.48% | 0.33% | 0.14% | 0.11% | 1.69% | 0.06% | 0.49% | 1.42% | 0.30% | 1.08% | 0.80% |
Checkpoint Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $20.33K, with a low forecast of $20.33K, and a high forecast of $20.33K. CKPT's average Quarter revenue forecast represents a 238.88% increase compared to the company's last Quarter revenue of $6.00K (Dec 23).
Checkpoint Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $-10.17M | $-7.70M | $-16.20M | $-25.65M | $-16.64M | $-10.66M | $-14.16M | $-16.86M | $-29.76M | $-11.27M | $-9.14M | $-6.50M | $-10.22M | $-4.93M | $-4.64M | $-3.28M | $-8.83M | $-5.21M | $-4.79M | $-5.89M | $-8.77M | $-4.38M |
| Avg Forecast | $-31.46M | $-22.03M | $-15.03M | $-4.53M | $-20.33K | $-20.33K | $-15.50K | $-20.33K | $-30.00K | $-16.67K | $-5.00K | $-12.50K | $-40.00K | $-11.44M | $-17.50K | $-10.58M | $-70.00K | $-114.00K | $-114.00K | $-7.16M | $-82.50K | $-193.33K | $-393.33K | $-4.54M | $-400.00K | $-566.67K | $-740.00K | $-7.85M | $-8.09M | $-5.26M |
| High Forecast | $-31.46M | $-22.03M | $-15.03M | $-4.53M | $-20.33K | $-20.33K | $-15.50K | $-20.33K | $-30.00K | $-16.67K | $-5.00K | $-12.50K | $-40.00K | $-9.15M | $-17.50K | $-8.47M | $-70.00K | $-114.00K | $-114.00K | $-5.72M | $-82.50K | $-193.33K | $-393.33K | $-3.63M | $-400.00K | $-566.67K | $-740.00K | $-6.28M | $-6.47M | $-4.21M |
| Low Forecast | $-31.46M | $-22.03M | $-15.03M | $-4.53M | $-20.33K | $-20.33K | $-15.50K | $-20.33K | $-30.00K | $-16.67K | $-5.00K | $-12.50K | $-40.00K | $-13.73M | $-17.50K | $-12.70M | $-70.00K | $-114.00K | $-114.00K | $-8.59M | $-82.50K | $-193.33K | $-393.33K | $-5.45M | $-400.00K | $-566.67K | $-740.00K | $-9.42M | $-9.70M | $-6.31M |
| Surprise % | - | - | - | - | - | - | - | - | 338.97% | 462.05% | 3239.00% | 2051.92% | 416.10% | 0.93% | 809.37% | 1.59% | 425.09% | 98.82% | 80.21% | 0.91% | 123.94% | 25.50% | 11.81% | 0.72% | 22.07% | 9.19% | 6.48% | 0.75% | 1.08% | 0.83% |
undefined analysts predict CKPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Checkpoint Therapeutics's previous annual EBITDA (undefined) of $NaN.
Checkpoint Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-19.13M | $-5.72M | $-16.52M | $-2.87M | $-25.36M | $-10.51M | $-14.10M | $-16.82M | $-29.74M | $-11.27M | $-9.14M | $-6.50M | $-10.22M | $-4.93M | $-4.64M | $-3.28M | $-8.83M | $-5.21M | $-4.79M | $-5.89M | $-8.77M | $-4.38M |
| Avg Forecast | $4.75M | $4.75M | $2.19M | $-4.02M | $-5.72M | $-5.36M | $-11.14M | $-10.00M | $-21.00M | $-27.76M | $-28.05M | $-38.06M | $-45.44M | $-11.44M | $-59.17M | $-10.59M | $-56.25M | $-49.68M | $-37.99M | $-7.16M | $-29.22M | $-29.22M | $-32.87M | $-4.54M | $-60.88M | $-60.88M | $-57.53M | $-7.85M | $-8.09M | $-5.26M |
| High Forecast | $4.75M | $4.75M | $2.19M | $-4.02M | $-5.72M | $-5.36M | $-11.14M | $-10.00M | $-19.02M | $-27.76M | $-28.05M | $-38.06M | $-45.44M | $-9.15M | $-59.17M | $-8.47M | $-56.25M | $-49.68M | $-37.99M | $-5.72M | $-29.22M | $-29.22M | $-32.87M | $-3.63M | $-60.88M | $-60.88M | $-57.53M | $-6.28M | $-6.47M | $-4.21M |
| Low Forecast | $4.75M | $4.75M | $2.19M | $-4.02M | $-5.72M | $-5.36M | $-11.14M | $-10.00M | $-22.71M | $-27.76M | $-28.05M | $-38.06M | $-45.44M | $-13.73M | $-59.17M | $-12.71M | $-56.25M | $-49.68M | $-37.99M | $-8.59M | $-29.22M | $-29.22M | $-32.87M | $-5.45M | $-60.88M | $-60.88M | $-57.53M | $-9.42M | $-9.70M | $-6.31M |
| Surprise % | - | - | - | - | - | - | - | - | 0.91% | 0.21% | 0.59% | 0.08% | 0.56% | 0.92% | 0.24% | 1.59% | 0.53% | 0.23% | 0.24% | 0.91% | 0.35% | 0.17% | 0.14% | 0.72% | 0.14% | 0.09% | 0.08% | 0.75% | 1.08% | 0.83% |
Checkpoint Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CKPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Checkpoint Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $1.88M | $2.24M | $2.28M | $2.29M | $2.48M | $1.85M | $2.13M | $2.24M | $2.13M | $1.92M | $2.11M | $2.37M | $2.12M | $2.43M | $1.69M | $1.68M | $2.15M | $1.62M | $1.76M | $1.70M | $2.19M | $1.40M |
| Avg Forecast | $1.09B | $762.86M | $520.47M | $156.89M | $704.06K | $704.06K | $536.71K | $704.06K | $1.04M | $577.12K | $173.13K | $432.83K | $1.39M | $807.94K | $605.96K | $807.94K | $2.42M | $3.95M | $3.95M | $4.93M | $2.86M | $6.69M | $13.62M | $19.97M | $13.85M | $19.62M | $25.62M | $40.82M | $11.02M | $29.87M |
| High Forecast | $1.09B | $762.86M | $520.47M | $156.89M | $704.06K | $704.06K | $536.71K | $704.06K | $1.04M | $577.12K | $173.13K | $432.83K | $1.39M | $807.94K | $605.96K | $807.94K | $2.42M | $3.95M | $3.95M | $4.93M | $2.86M | $6.69M | $13.62M | $19.97M | $13.85M | $19.62M | $25.62M | $40.82M | $13.23M | $35.84M |
| Low Forecast | $1.09B | $762.86M | $520.47M | $156.89M | $704.06K | $704.06K | $536.71K | $704.06K | $1.04M | $577.12K | $173.13K | $432.83K | $1.39M | $807.94K | $605.96K | $807.94K | $2.42M | $3.95M | $3.95M | $4.93M | $2.86M | $6.69M | $13.62M | $19.97M | $13.85M | $19.62M | $25.62M | $40.82M | $8.82M | $23.89M |
| Surprise % | - | - | - | - | - | - | - | - | 1.81% | 3.87% | 13.17% | 5.30% | 1.79% | 2.28% | 3.51% | 2.78% | 0.88% | 0.49% | 0.54% | 0.48% | 0.74% | 0.36% | 0.12% | 0.08% | 0.16% | 0.08% | 0.07% | 0.04% | 0.20% | 0.05% |
Checkpoint Therapeutics's average Quarter SG&A projection for Mar 24 is $704.06K, based on 1 Wall Street analysts, with a range of $704.06K to $704.06K. The forecast indicates a -62.47% fall compared to CKPT last annual SG&A of $1.88M (Dec 23).
Checkpoint Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.69 | $-0.29 | $-0.00 | $-0.24 | $-2.87 | $-1.19 | $-1.61 | $-1.98 | $-3.79 | $-1.43 | $-1.21 | $-0.93 | $-1.81 | $-0.87 | $-0.90 | $-0.64 | $-1.73 | $-1.51 | $-1.47 | $-1.83 | $-3.54 | $-1.99 |
| Avg Forecast | $0.13 | $0.13 | $0.06 | $-0.11 | $-0.16 | $-0.15 | $-0.30 | $-0.27 | $-0.57 | $-0.76 | $-0.77 | $-1.04 | $-1.24 | $-1.38 | $-1.62 | $-1.35 | $-1.54 | $-1.36 | $-1.04 | $-1.05 | $-0.80 | $-0.80 | $-0.90 | $-1.27 | $-1.67 | $-1.67 | $-1.57 | $-2.70 | $-0.18 | $-0.30 |
| High Forecast | $0.13 | $0.13 | $0.06 | $-0.11 | $-0.16 | $-0.15 | $-0.30 | $-0.27 | $-0.52 | $-0.76 | $-0.77 | $-1.04 | $-1.24 | $-1.38 | $-1.62 | $-1.35 | $-1.54 | $-1.36 | $-1.04 | $-1.05 | $-0.80 | $-0.80 | $-0.90 | $-1.27 | $-1.67 | $-1.67 | $-1.57 | $-2.70 | $-0.15 | $-0.24 |
| Low Forecast | $0.13 | $0.13 | $0.06 | $-0.11 | $-0.16 | $-0.15 | $-0.30 | $-0.27 | $-0.62 | $-0.76 | $-0.77 | $-1.04 | $-1.24 | $-1.38 | $-1.62 | $-1.35 | $-1.54 | $-1.36 | $-1.04 | $-1.05 | $-0.80 | $-0.80 | $-0.90 | $-1.27 | $-1.67 | $-1.67 | $-1.57 | $-2.70 | $-0.22 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | 1.20% | 0.38% | 0.00% | 0.23% | 2.31% | 0.87% | 0.99% | 1.47% | 2.46% | 1.05% | 1.16% | 0.88% | 2.27% | 1.09% | 1.00% | 0.51% | 1.04% | 0.90% | 0.93% | 0.68% | 19.67% | 6.62% |
According to undefined Wall Street analysts, Checkpoint Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CKPT previous annual EPS of $NaN (undefined).
Checkpoint Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KOD | Kodiak Sciences | $2.68 | $32.80 | 1123.88% | Buy |
| CUE | Cue Biopharma | $0.57 | $5.00 | 777.19% | Buy |
| CKPT | Checkpoint Therapeutics | $2.52 | $20.00 | 693.65% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.28 | $10.00 | 681.25% | Buy |
| SPRO | Spero Therapeutics | $1.33 | $10.00 | 651.88% | Buy |
| CTMX | CytomX Therapeutics | $1.21 | $5.77 | 376.86% | Buy |
| ATXI | Avenue Therapeutics | $2.76 | $12.00 | 334.78% | Buy |
| LUMO | Lumos Pharma | $3.88 | $16.50 | 325.26% | Buy |
| ACHL | Achilles Therapeutics | $0.71 | $2.00 | 181.69% | Buy |
| TIL | Instil Bio | $64.79 | $78.25 | 20.77% | Hold |
CKPT Forecast FAQ
Is Checkpoint Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Checkpoint Therapeutics (CKPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CKPT's total ratings.
What are Checkpoint Therapeutics's analysts' financial forecasts?
Checkpoint Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $76.5K (high $76.5K, low $76.5K), average EBITDA is $-76.499K (high $-76.499K, low $-76.499K), average net income is $-32.218M (high $-32.218M, low $-32.218M), average SG&A $2.65M (high $2.65M, low $2.65M), and average EPS is $-0.882 (high $-0.882, low $-0.882). CKPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $73.06M (high $73.06M, low $73.06M), average EBITDA is $-73.055M (high $-73.055M, low $-73.055M), average net income is $7.67M (high $7.67M, low $7.67M), average SG&A $2.53B (high $2.53B, low $2.53B), and average EPS is $0.21 (high $0.21, low $0.21).
Did the CKPT's actual financial results beat the analysts' financial forecasts?
Based on Checkpoint Therapeutics's last annual report (Dec 2022), the company's revenue was $192K, beating the average analysts forecast of $104.17K by 84.32%. Apple's EBITDA was $-53.882M, beating the average prediction of $-22.078M by 144.06%. The company's net income was $-66.915M, missing the average estimation of $-127M by -47.16%. Apple's SG&A was $8.7M, beating the average forecast of $3.61M by 141.20%. Lastly, the company's EPS was $-7.57, beating the average prediction of $-5.589 by 35.44%. In terms of the last quarterly report (Dec 2023), Checkpoint Therapeutics's revenue was $6K, missing the average analysts' forecast of $30K by -80.00%. The company's EBITDA was $-10.169M, beating the average prediction of $-30K by 33796.67%. Checkpoint Therapeutics's net income was $-19.128M, missing the average estimation of $-21.003M by -8.93%. The company's SG&A was $1.88M, beating the average forecast of $1.04M by 80.59%. Lastly, the company's EPS was $-0.69, beating the average prediction of $-0.575 by 20.00%